Genetic variation can reshape how people respond to medications by altering drug metabolism, target interactions, and immune recognition. Pharmacogenomics studies how common genetic polymorphisms—stable differences in DNA sequence between individuals—modify drug absorption, distribution, metabolism, excretion, and target sensitivity. This has direct consequences for therapeutic efficacy and the risk of adverse drug reactions, and these effects are documented in clinical guidelines and regulatory labeling.
Mechanisms and well-documented examples
Polymorphisms in genes encoding drug-metabolizing enzymes such as CYP450 family members change enzymatic activity and thus plasma drug levels. For example, variants in CYP2D6 and CYP2C19 classify patients as poor, intermediate, normal, or ultrarapid metabolizers, affecting response to antidepressants, antiplatelet drugs, and opioids. Clinical implementation guidance from Teri E. Klein Stanford University and the Clinical Pharmacogenetics Implementation Consortium at PharmGKB describes genotype-based dosing adjustments and drug selection to improve outcomes. Genetic variation in drug targets or pathways also matters: thiopurine S-methyltransferase TPMT variation, described in work by Mary Relling St. Jude Children’s Research Hospital, predicts life-threatening toxicity from standard doses of thiopurine chemotherapy and guides dose reduction. Immunogenetic markers can predict severe immune-mediated reactions; the association between HLA-B star 57 colon 01 and abacavir hypersensitivity identified by Andrew J. Mallal Queensland Institute of Medical Research led to routine pre-prescription screening and substantial reductions in preventable reactions.
Clinical consequences, relevance, and social context
When genetic testing is used, clinicians can reduce preventable harms and avoid ineffective therapies, improving safety and cost-effectiveness. The U.S. Food and Drug Administration includes pharmacogenomic biomarkers on many drug labels and recommends testing for selected drug-gene pairs where evidence supports actionability. However, genetics is one of several determinants of response. Age, kidney and liver function, comorbidities, interacting medications, diet, and adherence all influence outcomes and must be considered alongside genotype.
Population differences in allele frequencies create important equity and territorial considerations. Some metabolism-altering alleles are more common in specific ancestral groups, which changes the population-level risk of toxicity or treatment failure and affects screening priorities in different regions. Limited access to testing and variable representation of ancestries in research can deepen disparities, so implementation requires culturally informed communication and infrastructure sensitive to local health systems.
Policy and practice continue to evolve. High-quality randomized trials and observational studies, regulatory guidance from the U.S. Food and Drug Administration, and consensus guidelines from CPIC as documented by Teri E. Klein Stanford University support targeted use of pharmacogenomic information. Integration into electronic health records, clinician education, and equitable access are necessary to realize benefits while avoiding misapplication. Thoughtful deployment recognizes both the power of genetic information and its limits in the complex, social context of medication use.